Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2014.08.081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Bioartificial Vascular Pancreas.
J Tissue Eng
June 2021
Department of Biomedical Engineering, Yale School of Engineering and Applied Science, New Haven, CT, USA.
Transplantation of pancreatic islets has been shown to be effective, in some patients, for the long-term treatment of type 1 diabetes. However, transplantation of islets into either the portal vein or the subcutaneous space can be limited by insufficient oxygen transfer, leading to islet loss. Furthermore, oxygen diffusion limitations can be magnified when islet numbers are increased dramatically, as in translating from rodent studies to human-scale treatments.
View Article and Find Full Text PDFLong-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients.
Postepy Kardiol Interwencyjnej
December 2020
Department of Cardiology, Istanbul Medipol University, Istanbul, Turkey.
Introduction: Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS.
Aim: To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS.
Everolimus-eluting bioresorbable coronary scaffold in Asian patients: A 2-year follow-up.
J Pak Med Assoc
December 2020
Department of Cardiology, Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan.
Indo-Pakistan population has one of the highest risk of coronary artery disease (CAD) in the world. Percutaneous interventions with the use of stents has been the mainstay of treatment for CAD, evolving from balloon angioplasty to bare metal stents and then to drug eluting stents. However, there are a few drawbacks related to the metal implant in the coronary, leading to the development of bio-resorbable vascular scaffolds (BVS).
View Article and Find Full Text PDFMagmaris™ resorbable magnesium scaffold: state-of-art review.
Future Cardiol
July 2019
San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy.
Bioresorbable scaffolds (BRS) have been advocated as the 'fourth revolution' in interventional cardiology because they could provide temporary scaffolding and then 'disappear' (resorb) potentially significantly improving coronary artery disease treatment. BRS technology has gradually matured, and there are many devices available worldwide, which are currently undergoing preclinical or clinical testing. Due to the concerns related to polylactide scaffolds, magnesium alloy is now one of the most promising resorbable technologies despite available evidences on its performances are limited to small observational studies.
View Article and Find Full Text PDFBVS, RDN, IABP: The Afghanistan of interventional cardiology trials.
Indian Heart J
July 2018
Department of Cardiology, New Delhi, India. Electronic address:
In the field of medicine and cardiology newer therapy and devices have been launched with a huge promise and a lot of hype. Unfortunately, over the course of time, a good many of them like biovascular scaffold, renal denervation and intra-aortic balloon pump have failed to live up to their initial promise so much so that some of them have been withdrawn. The reason for this downfall may be multifold from incomplete understanding of the patho-physiology of disease, incomplete understanding of mechanism of action of the therapy, in-appropriate application in clinical practice, in-efficient therapy development related to flawed trial design, regulatory impediments placed on the trials or deficits in application of scientific techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!